{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:30:06Z","timestamp":1785450606712,"version":"3.56.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guangzhou key laboratory of construction and application of new drug screening model systems","award":["201805010006"],"award-info":[{"award-number":["201805010006"]}]},{"name":"Key Laboratory of New Drug Discovery and Evaluation of ordinary universities of Guangdong province","award":["2017KSYS002"],"award-info":[{"award-number":["2017KSYS002"]}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","award":["Z155080000004"],"award-info":[{"award-number":["Z155080000004"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10787-025-01659-4","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T07:45:52Z","timestamp":1739605552000},"page":"1221-1236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions"],"prefix":"10.1007","volume":"33","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkai","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhui","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-5673","authenticated-orcid":false,"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"1659_CR1","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.2147\/ccid.S389697","volume":"15","author":"E Araviiskaia","year":"2022","unstructured":"Araviiskaia E, Pincelli C, Sparavigna A, Luger T (2022) The role of a novel generation of emollients, \u2018emollients plus\u2019, in atopic dermatitis. Clin Cosmet Investig Dermatol 15:2705\u20132719. https:\/\/doi.org\/10.2147\/ccid.S389697","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"1659_CR2","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2020.2240","volume":"156","author":"MM Asgari","year":"2020","unstructured":"Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr (2020) Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol 156(10):1066\u20131073. https:\/\/doi.org\/10.1001\/jamadermatol.2020.2240","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1659_CR3","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1111\/jgs.19036","volume":"72","author":"CA Austin","year":"2024","unstructured":"Austin CA, Seligman B, Shan-Bala S, Kuchel GA, Loh KP, Kistler CE, Batsis JA (2024) Aging precisely: precision medicine through the lens of an older adult. J Am Geriatr Soc 72(10):2972\u20132980. https:\/\/doi.org\/10.1111\/jgs.19036","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"1659_CR4","doi-asserted-by":"publisher","first-page":"e046476","DOI":"10.1136\/bmjopen-2020-046476","volume":"11","author":"E Axon","year":"2021","unstructured":"Axon E, Chalmers JR, Santer M, Ridd MJ, Lawton S, Langan SM, Grindlay DJC, Muller I, Roberts A, Ahmed A, Williams HC, Thomas KS (2021) Safety of topical corticosteroids in atopic eczema an umbrella review. BMJ Open 11(7):e046476. https:\/\/doi.org\/10.1136\/bmjopen-2020-046476","journal-title":"BMJ Open"},{"issue":"10","key":"1659_CR5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/molecules21101321","volume":"21","author":"A Azab","year":"2016","unstructured":"Azab A, Nassar A, Azab AN (2016) Anti-inflammatory activity of natural products. Molecules 21(10):1321. https:\/\/doi.org\/10.3390\/molecules21101321","journal-title":"Molecules"},{"issue":"5","key":"1659_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","volume":"151","author":"D Bakker","year":"2023","unstructured":"Bakker D, de Bruin-Weller M, Drylewicz J, van Wijk F, Thijs J (2023) Biomarkers in atopic dermatitis. J Allergy Clin Immunol 151(5):1163\u20131168. https:\/\/doi.org\/10.1016\/j.jaci.2023.01.019","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1659_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58(3):488\u2013520. https:\/\/doi.org\/10.1124\/pr.58.3.5","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1659_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12016-023-08963-3","volume":"65","author":"R Bhat","year":"2023","unstructured":"Bhat R, Tonutti A, Timilsina S, Selmi C, Gershwin ME (2023) Perspectives on mycophenolate mofetil in the management of autoimmunity. Clin Rev Allergy Immunol 65(1):86\u2013100. https:\/\/doi.org\/10.1007\/s12016-023-08963-3","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"1659_CR9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bjd.17932","volume":"181","author":"R Bissonnette","year":"2019","unstructured":"Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Guttman-Yassky E (2019) The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol 181(4):733\u2013742. https:\/\/doi.org\/10.1111\/bjd.17932","journal-title":"Br J Dermatol"},{"issue":"5","key":"1659_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Ports WC (2016) Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 175(5):902\u2013911. https:\/\/doi.org\/10.1111\/bjd.14871","journal-title":"Br J Dermatol"},{"issue":"6","key":"1659_CR11","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jdv.18925","volume":"37","author":"R Bissonnette","year":"2023","unstructured":"Bissonnette R, Saint-Cyr Proulx E, Jack C, Maari C (2023) Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research. J Eur Acad Dermatol Venereol 37(6):1168\u20131174. https:\/\/doi.org\/10.1111\/jdv.18925","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1659_CR12","doi-asserted-by":"publisher","unstructured":"Bitton A, Avlas S, Reichman H, Itan M, Karo-Atar D, Azouz NP, Munitz A (2020) A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci Immunol 5(44):eaaw2938. https:\/\/doi.org\/10.1126\/sciimmunol.aaw2938","DOI":"10.1126\/sciimmunol.aaw2938"},{"issue":"10086","key":"1659_CR13","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/s0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Shumel B (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389(10086):2287\u20132303. https:\/\/doi.org\/10.1016\/s0140-6736(17)31191-1","journal-title":"Lancet"},{"issue":"8","key":"1659_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamadermatol.2024.2131","volume":"160","author":"A Blauvelt","year":"2024","unstructured":"Blauvelt A, Guttman-Yassky E, Lynde C, Khattri S, Schlessinger J, Imafuku S, Silverberg JI (2024) Cendakimab in patients with moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 160(8):856\u2013864. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2131","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1659_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood.2019001866","volume":"135","author":"P Bucher","year":"2020","unstructured":"Bucher P, Erdmann T, Grondona P, Xu W, Schmitt A, Sch\u00fcrch C, Hailfinger S (2020) Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood 135(2):121\u2013132. https:\/\/doi.org\/10.1182\/blood.2019001866","journal-title":"Blood"},{"issue":"8","key":"1659_CR16","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1039\/c9an02041a","volume":"145","author":"MM Calabretta","year":"2020","unstructured":"Calabretta MM, Zangheri M, Lopreside A, Marchegiani E, Montali L, Simoni P, Roda A (2020) Precision medicine, bioanalytics and nanomaterials: toward a new generation of personalized portable diagnostics. Analyst 145(8):2841\u20132853. https:\/\/doi.org\/10.1039\/c9an02041a","journal-title":"Analyst"},{"issue":"1","key":"1659_CR17","doi-asserted-by":"publisher","first-page":"T66","DOI":"10.1016\/j.ad.2023.10.032","volume":"115","author":"JM Carrascosa-Carrillo","year":"2024","unstructured":"Carrascosa-Carrillo JM, Aterido A, Li T, Guill\u00e9n Y, Martinez S, Marsal S, Juli\u00e0 A (2024) Toward precision medicine in atopic dermatitis using molecular-based approaches. Actas Dermosifiliogr 115(1):T66-t75. https:\/\/doi.org\/10.1016\/j.ad.2023.10.032","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"1659_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.abd.2020.05.003","volume":"95","author":"S Chavez-Alvarez","year":"2020","unstructured":"Chavez-Alvarez S, Herz-Ruelas M, Villarreal-Martinez A, Ocampo-Candiani J, Garza-Garza R, Gomez-Flores M (2020) Azathioprine: its uses in dermatology. An Bras Dermatol 95(6):731\u2013736. https:\/\/doi.org\/10.1016\/j.abd.2020.05.003","journal-title":"An Bras Dermatol"},{"issue":"9","key":"1659_CR19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jval.2023.05.001","volume":"26","author":"W Chen","year":"2023","unstructured":"Chen W, Wang Y, Zemlyanska Y, Butani D, Wong NCB, Virabhak S, Teerawattananon Y (2023) Evaluating the value for money of precision medicine from early cycle to market access: a comprehensive review of approaches and challenges. Value Health 26(9):1425\u20131434. https:\/\/doi.org\/10.1016\/j.jval.2023.05.001","journal-title":"Value Health"},{"key":"1659_CR20","doi-asserted-by":"publisher","unstructured":"Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T, Cifuentes L, Ogg G (2019) Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med 11(515): eaax2945. https:\/\/doi.org\/10.1126\/scitranslmed.aax2945","DOI":"10.1126\/scitranslmed.aax2945"},{"issue":"8","key":"1659_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamadermatol.2016.1009","volume":"152","author":"CC Chi","year":"2016","unstructured":"Chi CC, Wang SH, Kirtschig G (2016) Safety of topical corticosteroids in pregnancy. JAMA Dermatol 152(8):934\u2013935. https:\/\/doi.org\/10.1001\/jamadermatol.2016.1009","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1659_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS (2021) JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 148(4):927\u2013940. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009","journal-title":"J Allergy Clin Immunol"},{"key":"1659_CR23","doi-asserted-by":"publisher","unstructured":"Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Chu DK (2024) Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol 132(3): 274\u2013312. https:\/\/doi.org\/10.1016\/j.anai.2023.11.009","DOI":"10.1016\/j.anai.2023.11.009"},{"issue":"6","key":"1659_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/bor.0000000000000972","volume":"35","author":"S Cohen","year":"2023","unstructured":"Cohen S, Reddy V (2023) Janus kinase inhibitors: efficacy and safety. Curr Opin Rheumatol 35(6):429\u2013434. https:\/\/doi.org\/10.1097\/bor.0000000000000972","journal-title":"Curr Opin Rheumatol"},{"issue":"15","key":"1659_CR25","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.3390\/molecules27154964","volume":"27","author":"L Crocetti","year":"2022","unstructured":"Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP (2022) An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules 27(15):4964. https:\/\/doi.org\/10.3390\/molecules27154964","journal-title":"Molecules"},{"issue":"3","key":"1659_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G, Guttman-Yassky E (2024) OX40 in the pathogenesis of atopic dermatitis\u2014a new therapeutic target. Am J Clin Dermatol 25(3):447\u2013461. https:\/\/doi.org\/10.1007\/s40257-023-00838-9","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1659_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41431-023-01464-z","volume":"31","author":"AM D\u2019Gama","year":"2023","unstructured":"D\u2019Gama AM, Agrawal PB (2023) Genomic medicine in neonatal care: progress and challenges. Eur J Hum Genet 31(12):1357\u20131363. https:\/\/doi.org\/10.1038\/s41431-023-01464-z","journal-title":"Eur J Hum Genet"},{"key":"1659_CR28","doi-asserted-by":"publisher","unstructured":"Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, Chu DK (2023) Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health 7(1): 13\u201325. https:\/\/doi.org\/10.1016\/s2352-4642(22)00283-8","DOI":"10.1016\/s2352-4642(22)00283-8"},{"issue":"10415","key":"1659_CR29","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/s0140-6736(23)01619-7","volume":"402","author":"S Devjani","year":"2023","unstructured":"Devjani S, Engel PV, Javadi SS, Smith B, Wu JJ (2023) Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis. Lancet 402(10415):1833\u20131834. https:\/\/doi.org\/10.1016\/s0140-6736(23)01619-7","journal-title":"Lancet"},{"issue":"6","key":"1659_CR30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.fmre.2022.07.003","volume":"2","author":"X Dong","year":"2022","unstructured":"Dong X, Xiao T, Chen B, Lu Y, Zhou W (2022a) Precision medicine via the integration of phenotype-genotype information in neonatal genome project. Fundam Res 2(6):873\u2013884. https:\/\/doi.org\/10.1016\/j.fmre.2022.07.003","journal-title":"Fundam Res"},{"issue":"9","key":"1659_CR31","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1111\/bcp.15361","volume":"88","author":"Z Dong","year":"2022","unstructured":"Dong Z, Ye X, Chen C, Wang R, Liu D, Xu X, He J (2022b) Thromboembolic events in Janus kinase inhibitors: a pharmacovigilance study from 2012 to 2021 based on the food and drug administration\u2019s adverse event reporting system. Br J Clin Pharmacol 88(9):4180\u20134190. https:\/\/doi.org\/10.1111\/bcp.15361","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1659_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"XP Duan","year":"2024","unstructured":"Duan XP, Qin BD, Jiao XD, Liu K, Wang Z, Zang YS (2024) New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Ther 9(1):57. https:\/\/doi.org\/10.1038\/s41392-024-01760-0","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1659_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666x.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E (2021) The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol 17(8):835\u2013852. https:\/\/doi.org\/10.1080\/1744666x.2021.1940962","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"1659_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40257-023-00780-w","volume":"24","author":"LF Eichenfield","year":"2023","unstructured":"Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Werth J (2023) Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged \u2265 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol 24(4):623\u2013635. https:\/\/doi.org\/10.1007\/s40257-023-00780-w","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1659_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","volume":"20","author":"P Facheris","year":"2023","unstructured":"Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E (2023) The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol 20(5):448\u2013474. https:\/\/doi.org\/10.1038\/s41423-023-00992-4","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"1659_CR36","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.3390\/cells10113176","volume":"10","author":"N Fern\u00e1ndez-Gallego","year":"2021","unstructured":"Fern\u00e1ndez-Gallego N, S\u00e1nchez-Madrid F, Cibrian D (2021) Role of AHR ligands in skin homeostasis and cutaneous inflammation. Cells 10(11):3176. https:\/\/doi.org\/10.3390\/cells10113176","journal-title":"Cells"},{"issue":"2","key":"1659_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40257-022-00744-6","volume":"24","author":"FS Frech","year":"2023","unstructured":"Frech FS, Hernandez L, Urbonas R, Zaken GA, Dreyfuss I, Nouri K (2023) Hypertrophic scars and keloids: advances in treatment and review of established therapies. Am J Clin Dermatol 24(2):225\u2013245. https:\/\/doi.org\/10.1007\/s40257-022-00744-6","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1659_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1248\/bpb.b19-00088","volume":"43","author":"M Fujii","year":"2020","unstructured":"Fujii M (2020) Current understanding of pathophysiological mechanisms of atopic dermatitis: interactions among skin barrier dysfunction, immune abnormalities and pruritus. Biol Pharm Bull 43(1):12\u201319. https:\/\/doi.org\/10.1248\/bpb.b19-00088","journal-title":"Biol Pharm Bull"},{"issue":"14","key":"1659_CR39","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-015-0463-1","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP (2015) Roflumilast: a review in COPD. Drugs 75(14):1645\u20131656. https:\/\/doi.org\/10.1007\/s40265-015-0463-1","journal-title":"Drugs"},{"issue":"6","key":"1659_CR40","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/bjd.16240","volume":"178","author":"LAA Gerbens","year":"2018","unstructured":"Gerbens LAA, Hamann SAS, Brouwer MWD, Roekevisch E, Leeflang MMG, Spuls PI (2018) Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol 178(6):1288\u20131296. https:\/\/doi.org\/10.1111\/bjd.16240","journal-title":"Br J Dermatol"},{"issue":"6","key":"1659_CR41","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, Guttman-Yassky E (2012) Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130(6):1344\u20131354. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.012","journal-title":"J Allergy Clin Immunol"},{"issue":"3 Suppl 1","key":"1659_CR42","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","volume":"78","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA (2018) Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 78(3 Suppl 1):S28-s36. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1659_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bjd.21669","volume":"187","author":"V Goulden","year":"2022","unstructured":"Goulden V, Ling TC, Babakinejad P, Dawe R, Eadie E, Fassihi H, Exton LS (2022) British association of dermatologists and british photodermatology group guidelines for narrowband ultraviolet B phototherapy 2022. Br J Dermatol 187(3):295\u2013308. https:\/\/doi.org\/10.1111\/bjd.21669","journal-title":"Br J Dermatol"},{"issue":"3","key":"1659_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40521-020-00271-x","volume":"7","author":"J Gupta","year":"2020","unstructured":"Gupta J, Margolis DJ (2020) Filaggrin gene mutations with special reference to atopic dermatitis. Curr Treat Options Allergy 7(3):403\u2013413. https:\/\/doi.org\/10.1007\/s40521-020-00271-x","journal-title":"Curr Treat Options Allergy"},{"issue":"1","key":"1659_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","volume":"48","author":"C Guti\u00e9rrez-V\u00e1zquez","year":"2018","unstructured":"Guti\u00e9rrez-V\u00e1zquez C, Quintana FJ (2018) Regulation of the immune response by the aryl hydrocarbon receptor. Immunity 48(1):19\u201333. https:\/\/doi.org\/10.1016\/j.immuni.2017.12.012","journal-title":"Immunity"},{"issue":"5","key":"1659_CR46","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","volume":"78","author":"E Guttman-Yassky","year":"2018","unstructured":"Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Lebwohl MG (2018) Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial. J Am Acad Dermatol 78(5):872-881.e876. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1659_CR47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","volume":"72","author":"T Hajar","year":"2015","unstructured":"Hajar T, Leshem YA, Hanifin JM, Nedorost ST, Lio PA, Paller AS, Simpson EL (2015) A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol 72(3):541-549.e542. https:\/\/doi.org\/10.1016\/j.jaad.2014.11.024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1659_CR48","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1002\/ski2.268","volume":"3","author":"J Harvey","year":"2023","unstructured":"Harvey J, Lax SJ, Lowe A, Santer M, Lawton S, Langan SM, Thomas KS (2023) The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review. Skin Health Dis 3(5):e268. https:\/\/doi.org\/10.1002\/ski2.268","journal-title":"Skin Health Dis"},{"issue":"3","key":"1659_CR49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","volume":"151","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Yokozeki H, Karasuyama H, Satoh T (2023) IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin. J Allergy Clin Immunol 151(3):737-746.e736. https:\/\/doi.org\/10.1016\/j.jaci.2022.11.009","journal-title":"J Allergy Clin Immunol"},{"issue":"1s","key":"1659_CR50","doi-asserted-by":"publisher","first-page":"s8","DOI":"10.1097\/der.0000000000000711","volume":"32","author":"S Hassan","year":"2021","unstructured":"Hassan S, Hamideh N, Poulos C, Cheema S, Rangwani S, Lio PA (2021) Atopic dermatitis biomarkers and the movement toward personalized treatment. Dermatitis 32(1s):s8\u2013s14. https:\/\/doi.org\/10.1097\/der.0000000000000711","journal-title":"Dermatitis"},{"issue":"2","key":"1659_CR51","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2020.05.121","volume":"83","author":"WR Heymann","year":"2020","unstructured":"Heymann WR (2020) Topical tacrolimus and malignancy risk: should the theory be put to rest? J Am Acad Dermatol 83(2):367\u2013368. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.121","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1659_CR52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40265-020-01298-9","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy SM (2020) Dupilumab: a review in chronic rhinosinusitis with nasal polyps. Drugs 80(7):711\u2013717. https:\/\/doi.org\/10.1007\/s40265-020-01298-9","journal-title":"Drugs"},{"key":"1659_CR53","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB (2022) JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol 13:1068260. https:\/\/doi.org\/10.3389\/fimmu.2022.1068260","journal-title":"Front Immunol"},{"issue":"4","key":"1659_CR54","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1080\/09546634.2021.1914315","volume":"33","author":"H Husein-ElAhmed","year":"2022","unstructured":"Husein-ElAhmed H, Steinhoff M (2022) Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence. J Dermatolog Treat 33(4):1838\u20131843. https:\/\/doi.org\/10.1080\/09546634.2021.1914315","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1659_CR55","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/exd.14435","volume":"30","author":"J Hwang","year":"2021","unstructured":"Hwang J, Thompson A, Jaros J, Blackcloud P, Hsiao J, Shi VY (2021) Updated understanding of Staphylococcus aureus in atopic dermatitis: from virulence factors to commensals and clonal complexes. Exp Dermatol 30(10):1532\u20131545. https:\/\/doi.org\/10.1111\/exd.14435","journal-title":"Exp Dermatol"},{"issue":"6","key":"1659_CR56","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3390\/pharmaceutics15061635","volume":"15","author":"AE In \u2019t Veld","year":"2023","unstructured":"In \u2019t Veld AE, Jansen MAA, de Kam ML, Yavuz Y, Moes D, Oudhoff KA, Moerland M (2023) Immune monitoring of mycophenolate mofetil activity in healthy volunteers using ex vivo T cell function assays. Pharmaceutics 15(6):1635. https:\/\/doi.org\/10.3390\/pharmaceutics15061635","journal-title":"Pharmaceutics"},{"issue":"11","key":"1659_CR57","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/all.13460","volume":"73","author":"K Iwamoto","year":"2018","unstructured":"Iwamoto K, N\u00fcmm TJ, Koch S, Herrmann N, Leib N, Bieber T (2018) Langerhans and inflammatory dendritic epidermal cells in atopic dermatitis are tolerized toward TLR2 activation. Allergy 73(11):2205\u20132213. https:\/\/doi.org\/10.1111\/all.13460","journal-title":"Allergy"},{"issue":"1","key":"1659_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/cts.12884","volume":"14","author":"KB Johnson","year":"2021","unstructured":"Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Snowdon JL (2021) Precision medicine, AI, and the future of personalized health care. Clin Transl Sci 14(1):86\u201393. https:\/\/doi.org\/10.1111\/cts.12884","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1659_CR59","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.alit.2020.02.006","volume":"69","author":"N Katoh","year":"2020","unstructured":"Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Yamamoto-Hanada K (2020) Japanese guidelines for atopic dermatitis 2020. Allergol Int 69(3):356\u2013369. https:\/\/doi.org\/10.1016\/j.alit.2020.02.006","journal-title":"Allergol Int"},{"issue":"10","key":"1659_CR60","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Nemolizumab: First Approval. Drugs 82(10):1143\u20131150. https:\/\/doi.org\/10.1007\/s40265-022-01741-z","journal-title":"Drugs"},{"issue":"3","key":"1659_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","volume":"10","author":"BE Kim","year":"2018","unstructured":"Kim BE, Leung DYM (2018) Significance of skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res 10(3):207\u2013215. https:\/\/doi.org\/10.4168\/aair.2018.10.3.207","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"1659_CR62","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4168\/aair.2019.11.5.593","volume":"11","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Ahn K, Leung DYM (2019a) Interactions between atopic dermatitis and staphylococcus aureus infection: clinical implications. Allergy Asthma Immunol Res 11(5):593\u2013603. https:\/\/doi.org\/10.4168\/aair.2019.11.5.593","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"1659_CR63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM (2019b) Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc 40(2):84\u201392. https:\/\/doi.org\/10.2500\/aap.2019.40.4202","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"1659_CR64","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2340\/00015555-2318","volume":"96","author":"KC Ko","year":"2016","unstructured":"Ko KC, Tominaga M, Kamata Y, Umehara Y, Matsuda H, Takahashi N, Takamori K (2016) Possible antipruritic mechanism of cyclosporine A in atopic dermatitis. Acta Derm Venereol 96(5):624\u2013629. https:\/\/doi.org\/10.2340\/00015555-2318","journal-title":"Acta Derm Venereol"},{"key":"1659_CR65","doi-asserted-by":"publisher","unstructured":"Landis MN, Arya M, Smith S, Draelos Z, Usdan L, Tarabar S, Beebe JS (2022) Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol 187(6): 878\u2013887. https:\/\/doi.org\/10.1111\/bjd.21826","DOI":"10.1111\/bjd.21826"},{"issue":"16","key":"1659_CR66","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/cells13161398","volume":"13","author":"J Laska","year":"2024","unstructured":"Laska J, Tota M, \u0141acwik J, S\u0119dek \u0141, Gomu\u0142ka K (2024) IL-22 in atopic dermatitis. Cells 13(16):1398. https:\/\/doi.org\/10.3390\/cells13161398","journal-title":"Cells"},{"issue":"12","key":"1659_CR67","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3390\/pharmaceutics14122753","volume":"14","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Torres T (2022) OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on rocatinlimab and amlitelimab. Pharmaceutics 14(12):2753. https:\/\/doi.org\/10.3390\/pharmaceutics14122753","journal-title":"Pharmaceutics"},{"key":"1659_CR68","doi-asserted-by":"publisher","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, Orengo JM (2020) Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy 75(5): 1188\u20131204. https:\/\/doi.org\/10.1111\/all.14151","DOI":"10.1111\/all.14151"},{"key":"1659_CR69","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W (2018) Phosphodiesterase-4 Inhibitors for the treatment of inflammatory diseases. Front Pharmacol 9:1048. https:\/\/doi.org\/10.3389\/fphar.2018.01048","journal-title":"Front Pharmacol"},{"key":"1659_CR70","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jconrel.2024.03.007","volume":"368","author":"S Li","year":"2024","unstructured":"Li S, Li W, Wu X, Zhang B, Liu L, Yin L (2024) Immune cell-derived extracellular vesicles for precision therapy of inflammatory-related diseases. J Control Release 368:533\u2013547. https:\/\/doi.org\/10.1016\/j.jconrel.2024.03.007","journal-title":"J Control Release"},{"issue":"7","key":"1659_CR71","doi-asserted-by":"publisher","first-page":"e15142","DOI":"10.1111\/exd.15142","volume":"33","author":"S Lin","year":"2024","unstructured":"Lin S, Liu X, Jiang J, Ge W, Zhang Y, Li F, Chen H (2024) The involvement of keratinocytes in pruritus of chronic inflammatory dermatosis. Exp Dermatol 33(7):e15142. https:\/\/doi.org\/10.1111\/exd.15142","journal-title":"Exp Dermatol"},{"key":"1659_CR72","doi-asserted-by":"publisher","first-page":"604314","DOI":"10.3389\/fphar.2020.604314","volume":"11","author":"J Liu","year":"2020","unstructured":"Liu J, Lv B, Yin H, Zhu X, Wei H, Ding Y (2020) A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose and food effect study to evaluate the tolerance, pharmacokinetics of jaktinib, a new selective janus kinase inhibitor in healthy chinese volunteers. Front Pharmacol 11:604314. https:\/\/doi.org\/10.3389\/fphar.2020.604314","journal-title":"Front Pharmacol"},{"issue":"9","key":"1659_CR73","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/ph13090260","volume":"13","author":"G Magni","year":"2020","unstructured":"Magni G, Ceruti S (2020) Adenosine signalling in autoimmune disorders. Pharmaceuticals 13(9):260. https:\/\/doi.org\/10.3390\/ph13090260","journal-title":"Pharmaceuticals"},{"issue":"5","key":"1659_CR74","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/jcm4050858","volume":"4","author":"Y Mansouri","year":"2015","unstructured":"Mansouri Y, Guttman-Yassky E (2015) Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med 4(5):858\u2013873. https:\/\/doi.org\/10.3390\/jcm4050858","journal-title":"J Clin Med"},{"key":"1659_CR75","doi-asserted-by":"publisher","first-page":"125070","DOI":"10.1016\/j.ijpharm.2024.125070","volume":"670","author":"JE Mart\u00ednez-Jim\u00e9nez","year":"2024","unstructured":"Mart\u00ednez-Jim\u00e9nez JE, Sathisaran I, Reyes Figueroa F, Reyes S, L\u00f3pez-Nieves M, Vlaar CP, Duconge J (2024) A review of precision medicine in developing pharmaceutical products: perspectives and opportunities. Int J Pharm 670:125070. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.125070","journal-title":"Int J Pharm"},{"issue":"15","key":"1659_CR76","doi-asserted-by":"publisher","first-page":"8088","DOI":"10.3390\/ijms23158088","volume":"23","author":"B Mlynarczyk-Bonikowska","year":"2022","unstructured":"Mlynarczyk-Bonikowska B, Kowalewski C, Krolak-Ulinska A, Marusza W (2022) Molecular mechanisms of drug resistance in Staphylococcus aureus. Int J Mol Sci 23(15):8088. https:\/\/doi.org\/10.3390\/ijms23158088","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1659_CR77","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jid.2023.04.005","volume":"143","author":"RD Mortlock","year":"2023","unstructured":"Mortlock RD, Ma EC, Cohen JM, Damsky W (2023) Assessment of treatment-relevant immune biomarkers in psoriasis and atopic dermatitis: toward personalized medicine in dermatology. J Invest Dermatol 143(8):1412\u20131422. https:\/\/doi.org\/10.1016\/j.jid.2023.04.005","journal-title":"J Invest Dermatol"},{"key":"1659_CR78","doi-asserted-by":"publisher","unstructured":"Musters AH, Mashayekhi S, Harvey J, Axon E, Lax SJ, Flohr C, Spuls PI (2021) Phototherapy for atopic eczema. Cochrane Database Syst Rev 10(10): Cd013870. https:\/\/doi.org\/10.1002\/14651858.CD013870.pub2","DOI":"10.1002\/14651858.CD013870.pub2"},{"key":"1659_CR79","doi-asserted-by":"publisher","first-page":"e074678","DOI":"10.1136\/bmj-2022-074678","volume":"381","author":"G Nakafero","year":"2023","unstructured":"Nakafero G, Grainge MJ, Williams HC, Card T, Taal MW, Aithal GP, Abhishek A (2023) Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. BMJ 381:e074678. https:\/\/doi.org\/10.1136\/bmj-2022-074678","journal-title":"BMJ"},{"issue":"4","key":"1659_CR80","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kabashima K, Oda M, Nagata T (2021) Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol 85(4):854\u2013862. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"1659_CR81","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.3390\/ijms21186484","volume":"21","author":"B Nedoszytko","year":"2020","unstructured":"Nedoszytko B, Reszka E, Gutowska-Owsiak D, Trzeciak M, Lange M, Jarczak J, Kalinowski L (2020) Genetic and epigenetic aspects of atopic dermatitis. Int J Mol Sci 21(18):6484. https:\/\/doi.org\/10.3390\/ijms21186484","journal-title":"Int J Mol Sci"},{"key":"1659_CR82","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/jaa.S342051","volume":"15","author":"S Owji","year":"2022","unstructured":"Owji S, Caldas SA, Ungar B (2022) Management of atopic dermatitis: clinical utility of ruxolitinib. J Asthma Allergy 15:1527\u20131537. https:\/\/doi.org\/10.2147\/jaa.S342051","journal-title":"J Asthma Allergy"},{"issue":"5","key":"1659_CR83","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, Shumel B (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 83(5):1282\u20131293. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1659_CR84","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Hebert AA (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75(3):494-503.e496. https:\/\/doi.org\/10.1016\/j.jaad.2016.05.046","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1659_CR85","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/phpp.12546","volume":"36","author":"JB Park","year":"2020","unstructured":"Park JB, Jang JY, Kwon DI, Seong SH, Suh KS, Jang MS (2020a) The effectiveness of high-dose ultraviolet A-1 phototherapy for acute exacerbation of atopic dermatitis in Asians. Photodermatol Photoimmunol Photomed 36(4):263\u2013270. https:\/\/doi.org\/10.1111\/phpp.12546","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1659_CR86","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2020.00195","volume":"11","author":"YJ Park","year":"2020","unstructured":"Park YJ, Yoo SA, Kim M, Kim WU (2020b) The role of calcium-calcineurin-NFAT signaling pathway in health and autoimmune diseases. Front Immunol 11:195. https:\/\/doi.org\/10.3389\/fimmu.2020.00195","journal-title":"Front Immunol"},{"issue":"2","key":"1659_CR87","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/cpt.1401","volume":"106","author":"JR Parnes","year":"2019","unstructured":"Parnes JR, Sullivan JT, Chen L, Dias C (2019) Pharmacokinetics, safety, and tolerability of tezepelumab (AMG 157) in healthy and atopic dermatitis adult subjects. Clin Pharmacol Ther 106(2):441\u2013449. https:\/\/doi.org\/10.1002\/cpt.1401","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1659_CR88","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jaip.2023.03.022","volume":"11","author":"J Pena","year":"2023","unstructured":"Pena J, Zameza PA, Pixley JN, Remitz A, Feldman SR (2023) A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis. J Allergy Clin Immunol Pract 11(5):1347\u20131359. https:\/\/doi.org\/10.1016\/j.jaip.2023.03.022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1659_CR89","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13073-018-0525-6","volume":"10","author":"JF Petrosino","year":"2018","unstructured":"Petrosino JF (2018) The microbiome in precision medicine: the way forward. Genome Med 10(1):12. https:\/\/doi.org\/10.1186\/s13073-018-0525-6","journal-title":"Genome Med"},{"issue":"3","key":"1659_CR90","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.det.2017.02.007","volume":"35","author":"JC Prezzano","year":"2017","unstructured":"Prezzano JC, Beck LA (2017) Long-term treatment of atopic dermatitis. Dermatol Clin 35(3):335\u2013349. https:\/\/doi.org\/10.1016\/j.det.2017.02.007","journal-title":"Dermatol Clin"},{"key":"1659_CR91","doi-asserted-by":"publisher","first-page":"5528372","DOI":"10.1155\/2021\/5528372","volume":"2021","author":"HJ Qi","year":"2021","unstructured":"Qi HJ, Li LF (2021) New biologics for the treatment of atopic dermatitis: analysis of efficacy, safety, and paradoxical atopic dermatitis acceleration. Biomed Res Int 2021:5528372. https:\/\/doi.org\/10.1155\/2021\/5528372","journal-title":"Biomed Res Int"},{"issue":"4","key":"1659_CR92","doi-asserted-by":"publisher","first-page":"e2021146","DOI":"10.5826\/dpc.1104a146","volume":"11","author":"A Raimondo","year":"2021","unstructured":"Raimondo A, Lembo S (2021) Atopic dermatitis: epidemiology and clinical phenotypes. Dermatol Pract Concept 11(4):e2021146. https:\/\/doi.org\/10.5826\/dpc.1104a146","journal-title":"Dermatol Pract Concept"},{"issue":"9","key":"1659_CR93","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14656566.2019.1604688","volume":"20","author":"V Ramachandran","year":"2019","unstructured":"Ramachandran V, Cline A, Feldman SR, Strowd LC (2019) Evaluating crisaborole as a treatment option for atopic dermatitis. Expert Opin Pharmacother 20(9):1057\u20131063. https:\/\/doi.org\/10.1080\/14656566.2019.1604688","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"1659_CR94","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.3390\/jcm12093303","volume":"12","author":"M Rossi","year":"2023","unstructured":"Rossi M, Damiani C, Arisi M, Tomasi C, Tonon F, Venturini M, Calzavara-Pinton P (2023) Definition of the clinical characteristics of patients with moderate and severe atopic dermatitis for whom narrow-band UVB (NB-UVB) and medium-dose UVA1 phototherapies are still valuable treatment options at the age of biologics. J Clin Med 12(9):3303. https:\/\/doi.org\/10.3390\/jcm12093303","journal-title":"J Clin Med"},{"issue":"3","key":"1659_CR95","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ced\/llad379","volume":"49","author":"A Salava","year":"2024","unstructured":"Salava A, Remitz A (2024) Safety of topical tacrolimus and corticosteroids in young children with atopic dermatitis: a 5-year questionnaire-based follow-up study. Clin Exp Dermatol 49(3):276\u2013280. https:\/\/doi.org\/10.1093\/ced\/llad379","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1659_CR96","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG (2023) A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther 13(3):729\u2013749. https:\/\/doi.org\/10.1007\/s13555-023-00892-5","journal-title":"Dermatol Ther"},{"issue":"2","key":"1659_CR97","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","volume":"21","author":"J Schlessinger","year":"2020","unstructured":"Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, Vlahos B (2020) Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol 21(2):275\u2013284. https:\/\/doi.org\/10.1007\/s40257-020-00510-6","journal-title":"Am J Clin Dermatol"},{"key":"1659_CR98","doi-asserted-by":"publisher","unstructured":"Sidbury R, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Drucker AM, Davis DMR (2023) Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol 89(1): e1\u2013e20. https:\/\/doi.org\/10.1016\/j.jaad.2022.12.029","DOI":"10.1016\/j.jaad.2022.12.029"},{"key":"1659_CR99","doi-asserted-by":"publisher","unstructured":"Sideris N, Paschou E, Bakirtzi K, Kiritsi D, Papadimitriou I, Tsentemeidou A, Vakirlis E (2022) New and upcoming topical treatments for atopic dermatitis: a review of the literature. J Clin Med 11(17): 4974. https:\/\/doi.org\/10.3390\/jcm11174974","DOI":"10.3390\/jcm11174974"},{"issue":"3","key":"1659_CR100","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Kircik L (2024a) Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol 91(3):457\u2013465. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1659_CR101","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","volume":"25","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Tha\u00e7i D (2024b) Early and sustained improvements in symptoms and quality of life with upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: 52-week results from two phase III randomized clinical trials (measure up 1 and measure Up 2). Am J Clin Dermatol 25(3):485\u2013496. https:\/\/doi.org\/10.1007\/s40257-024-00853-4","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1659_CR102","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, Irvine AD, Stein Gold L, Blauvelt A, Seneschal J (2023) Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 388(12):1080\u20131091. https:\/\/doi.org\/10.1056\/NEJMoa2206714","journal-title":"N Engl J Med"},{"issue":"4","key":"1659_CR103","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","volume":"153","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Strober B, Feinstein B, Xu J, Guttman-Yassky E, Simpson EL, Wei Z (2024c) Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001). J Allergy Clin Immunol 153(4):1040-1049.e1012. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.924","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1659_CR104","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Weidinger S (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184(3):450\u2013463. https:\/\/doi.org\/10.1111\/bjd.19573","journal-title":"Br J Dermatol"},{"issue":"1","key":"1659_CR105","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Bansal A (2020) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1659_CR106","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Tha\u00e7i D, de Bruin-Weller M, Cork MJ (2023) Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE trial. Am J Clin Dermatol 24(4):609\u2013621. https:\/\/doi.org\/10.1007\/s40257-023-00785-5","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1659_CR107","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, Cote-Sierra J (2017) Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol 137(10):2110\u20132119. https:\/\/doi.org\/10.1016\/j.jid.2017.05.004","journal-title":"J Invest Dermatol"},{"key":"1659_CR108","doi-asserted-by":"publisher","first-page":"173242","DOI":"10.1016\/j.ejphar.2020.173242","volume":"881","author":"M Soeberdt","year":"2020","unstructured":"Soeberdt M, Kilic A, Abels C (2020) Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol 881:173242. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173242","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"1659_CR109","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1111\/all.14324","volume":"75","author":"LS Spekhorst","year":"2020","unstructured":"Spekhorst LS, Ari\u00ebns LFM, van der Schaft J, Bakker DS, Kamsteeg M, Oosting AJ, de Bruin-Weller MS (2020) Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry. Allergy 75(9):2376\u20132379. https:\/\/doi.org\/10.1111\/all.14324","journal-title":"Allergy"},{"issue":"6","key":"1659_CR110","first-page":"337","volume":"103","author":"SK Stacey","year":"2021","unstructured":"Stacey SK, McEleney M (2021) Topical corticosteroids: choice and application. Am Fam Physician 103(6):337\u2013343","journal-title":"Am Fam Physician"},{"issue":"7","key":"1659_CR111","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/genes11070747","volume":"11","author":"O Strianese","year":"2020","unstructured":"Strianese O, Rizzo F, Ciccarelli M, Galasso G, D\u2019Agostino Y, Salvati A, Rusciano MR (2020) Precision and personalized medicine: how genomic approach improves the management of cardiovascular and neurodegenerative disease. Genes 11(7):747. https:\/\/doi.org\/10.3390\/genes11070747","journal-title":"Genes"},{"key":"1659_CR112","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","volume":"9","author":"EB Thangam","year":"2018","unstructured":"Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, Saluja R (2018) The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol 9:1873. https:\/\/doi.org\/10.3389\/fimmu.2018.01873","journal-title":"Front Immunol"},{"issue":"2","key":"1659_CR113","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s13555-021-00500-4","volume":"11","author":"HL Tier","year":"2021","unstructured":"Tier HL, Balogh EA, Bashyam AM, Fleischer AB Jr, Spergel JM, Masicampo EJ, Feldman SR (2021) Tolerability of and adherence to topical treatments in atopic dermatitis: a narrative review. Dermatol Ther 11(2):415\u2013431. https:\/\/doi.org\/10.1007\/s13555-021-00500-4","journal-title":"Dermatol Ther"},{"issue":"1","key":"1659_CR114","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A, Eichenfield LF (2023) Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol 189(1):23\u201332. https:\/\/doi.org\/10.1093\/bjd\/ljad096","journal-title":"Br J Dermatol"},{"issue":"15","key":"1659_CR115","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.3390\/jcm11154431","volume":"11","author":"A Tsiogka","year":"2022","unstructured":"Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, Nicolaidou E, Stratigos A, Rigopoulos D, Gregoriou S (2022) The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review. J Clin Med 11(15):4431. https:\/\/doi.org\/10.3390\/jcm11154431","journal-title":"J Clin Med"},{"issue":"3","key":"1659_CR116","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaad.2023.10.026","volume":"90","author":"KA Veverka","year":"2024","unstructured":"Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A (2024) Safety and efficacy of eblasakimab, an interleukin 13 receptor \u03b11 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. J Am Acad Dermatol 90(3):504\u2013511. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.026","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"1659_CR117","doi-asserted-by":"publisher","first-page":"9412","DOI":"10.3390\/ijms21249412","volume":"21","author":"YH Vu","year":"2020","unstructured":"Vu YH, Hashimoto-Hachiya A, Takemura M, Yumine A, Mitamura Y, Nakahara T, Tsuji G (2020) IL-24 negatively regulates keratinocyte differentiation induced by tapinarof, an aryl hydrocarbon receptor modulator: implication in the treatment of atopic dermatitis. Int J Mol Sci 21(24):9412. https:\/\/doi.org\/10.3390\/ijms21249412","journal-title":"Int J Mol Sci"},{"key":"1659_CR118","doi-asserted-by":"publisher","first-page":"154980","DOI":"10.1016\/j.phymed.2023.154980","volume":"118","author":"Y Wei","year":"2023","unstructured":"Wei Y, Liu X, Jiang Y, Guan Q, Tian Y, Li J, Zhao P (2023) Maintenance of airway epithelial barrier integrity via the inhibition of AHR\/EGFR activation ameliorates chronic obstructive pulmonary disease using effective-component combination. Phytomedicine 118:154980. https:\/\/doi.org\/10.1016\/j.phymed.2023.154980","journal-title":"Phytomedicine"},{"issue":"1","key":"1659_CR119","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/ddg.14371","volume":"19","author":"T Werfel","year":"2021","unstructured":"Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, Ott H (2021) Update \u201cSystemic treatment of atopic dermatitis\u201d of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges 19(1):151\u2013168. https:\/\/doi.org\/10.1111\/ddg.14371","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"1659_CR120","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Ring J (2018) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 32(5):657\u2013682. https:\/\/doi.org\/10.1111\/jdv.14891","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1659_CR121","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Simpson EL (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184(3):437\u2013449. https:\/\/doi.org\/10.1111\/bjd.19574","journal-title":"Br J Dermatol"},{"issue":"5","key":"1659_CR122","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/bjd\/ljad032","volume":"188","author":"Y Wu","year":"2023","unstructured":"Wu Y, Gu C, Wang S, Yin H, Qiu Z, Luo Y, Li W (2023) Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab. Br J Dermatol 188(5):649\u2013660. https:\/\/doi.org\/10.1093\/bjd\/ljad032","journal-title":"Br J Dermatol"},{"issue":"10","key":"1659_CR123","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s13555-023-01010-1","volume":"13","author":"CJ Wynne","year":"2023","unstructured":"Wynne CJ, Cole A, Lemech C, Wang G, Zhang Y, Chen B, Sinclair R (2023) Safety, pharmacokinetics and preliminary efficacy of IL4-R\u03b1 monoclonal antibody AK120 in both healthy and atopic dermatitis subjects: a phase I, randomized, two-part, double-blind, placebo-controlled, dose-escalation. First-in-Human Clin Study Dermatol Ther 13(10):2357\u20132373. https:\/\/doi.org\/10.1007\/s13555-023-01010-1","journal-title":"First-in-Human Clin Study Dermatol Ther"},{"key":"1659_CR124","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Sun S (2020) The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210. https:\/\/doi.org\/10.1016\/j.intimp.2020.106210","journal-title":"Int Immunopharmacol"},{"issue":"16","key":"1659_CR125","doi-asserted-by":"publisher","first-page":"12975","DOI":"10.3390\/ijms241612975","volume":"24","author":"HL Yamaguchi","year":"2023","unstructured":"Yamaguchi HL, Yamaguchi Y, Peeva E (2023) Role of innate immunity in allergic contact dermatitis: an update. Int J Mol Sci 24(16):12975. https:\/\/doi.org\/10.3390\/ijms241612975","journal-title":"Int J Mol Sci"},{"key":"1659_CR126","doi-asserted-by":"publisher","first-page":"110142","DOI":"10.1016\/j.biopha.2020.110142","volume":"127","author":"F Yan","year":"2020","unstructured":"Yan F, Li F, Liu J, Ye S, Zhang Y, Jia J, Mo X (2020) The formulae and biologically active ingredients of Chinese herbal medicines for the treatment of atopic dermatitis. Biomed Pharmacother 127:110142. https:\/\/doi.org\/10.1016\/j.biopha.2020.110142","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1659_CR127","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/bjd.21776","volume":"187","author":"N Yang","year":"2022","unstructured":"Yang N, Chen L, Shao J, Jiang F, Liu J, Li Z (2022) Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab. Br J Dermatol 187(5):828\u2013830. https:\/\/doi.org\/10.1111\/bjd.21776","journal-title":"Br J Dermatol"},{"issue":"1","key":"1659_CR128","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, Kim HS, Kim B, Kim MB, Kim YH (2024) The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 38(1):52\u201361. https:\/\/doi.org\/10.1111\/jdv.19426","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1659_CR129","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","volume":"142","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T (2018) Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol 142(5):1375\u20131390. https:\/\/doi.org\/10.1016\/j.jaci.2018.09.005","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1659_CR130","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjd.20690","volume":"186","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Wu L, Lu Q, Gao X, Zhu X, Yao X, Zhang J (2022) The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 186(4):633\u2013641. https:\/\/doi.org\/10.1111\/bjd.20690","journal-title":"Br J Dermatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01659-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:17:12Z","timestamp":1742303832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01659-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":130,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01659-4","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}